Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.

MLA

Albers, Frank C., et al. “Biologic Treatment Eligibility for Real-World Patients with Severe Asthma: The IDEAL Study.” The Journal of Asthma : Official Journal of the Association for the Care of Asthma, vol. 55, no. 2, Feb. 2018, pp. 152–60. EBSCOhost, https://doi.org/10.1080/02770903.2017.1322611.

APA

Albers, F. C., Müllerová, H., Gunsoy, N. B., Shin, J.-Y., Nelsen, L. M., Bradford, E. S., Cockle, S. M., & Suruki, R. Y. (2018). Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study. The Journal of Asthma : Official Journal of the Association for the Care of Asthma, 55(2), 152–160. https://doi.org/10.1080/02770903.2017.1322611

Chicago

Albers, Frank C, Hana Müllerová, Necdet B Gunsoy, Ji-Yeon Shin, Linda M Nelsen, Eric S Bradford, Sarah M Cockle, and Robert Y Suruki. 2018. “Biologic Treatment Eligibility for Real-World Patients with Severe Asthma: The IDEAL Study.” The Journal of Asthma : Official Journal of the Association for the Care of Asthma 55 (2): 152–60. doi:10.1080/02770903.2017.1322611.